INFORMATION BY CANCER TYPE

CLL

Examining the Safety of CLL Medication
BY Nitin Jain, M.D.
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Drug Provides High Response Rate in CLL
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.
 
A Personalized Era in Chronic Lymphocytic Leukemia Treatment
BY Heather Millar
Researchers are identifying targets to treat chronic lymphocytic leukemia.
Expert Discusses Advances in Treating CLL
BY Gina Columbus
Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
 
The Final Chemo Cycle
BY Edward McClain
As Ed completes his final chemo cycle, he loses a friend.
Expert Answers: What's the Best Frontline Treatment for Chronic Lymphocytic Leukemia
BY Laura Panjwani
Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.
Change is on the Horizon for CLL Treatment, Expert Says
BY Gina Columbus
The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.
New Agents on Horizon in CLL, Though Advantages Are Not Yet Clear
Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.
Frontline Treatment for Chronic Lymphocytic Leukemia Not One-Size-Fits-All
BY Jason M. Broderick
There are now more personalized treatment options for patients with CLL. 
Arzerra Combination FDA Approved in Chronic Lymphocytic Leukemia
BY Silas Inman
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Cll CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.
Adult Acute Myeloid Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.
Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood acute lymphoblastic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.
Chronic Myelogenous Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of chronic myelogenous leukemia.
Hairy Cell Leukemia Treatment (PDQ®)
Expert-reviewed information summary about the treatment of hairy cell leukemia.
x
//For side ad protocol